Could NIB shares beat the market in 2024?

Will next year be better for this private health insurer's shares?

| More on:
A man looking at his laptop and thinking.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares have had an underwhelming time in 2023.

Since the start of the year, the private health insurer's shares have lost 4.5% of their value.

As a comparison, the ASX 200 index is up approximately 7% over the same period.

Will things be better for NIB shares in 2024?

There are a few factors that could have a major say on how NIB shares perform next year.

The first is the performance of the market as a whole. If interest rates are cut across the globe, it could give investor sentiment a major boost and drive shares higher.

Premium rate increases are another factor that could impact the company's share price. According to reports, the health insurance industry is seeking a 6% premium rate increase on average for next year.

While it is unclear if this will be approved, it is notably higher than what the market was expecting and compares to increases of 2.9% in 2023, 2.7% in 2022, and 2.74% in 2021. Goldman Sachs commented:

The 6% rate increase quoted in the AFR is higher than we expected noting claims cost inflation remains somewhat benign reflecting lower utilisation for mental health and rehab in particular.

What else?

Another factor to be aware of is the potential change to the NDIS.

NIB entered the NDIS market at the end of last year through the acquisition of plan manager, Maple. It raised $158 million to support its entry and has since made a number of other acquisitions, growing its presence in the market.

However, proposed changes to the NDIS could be a blow to its ambitions. A review is expected to be released in 2024.

Can its shares rise?

The good news is that Goldman Sachs has taken all the above into consideration and remains bullish on NIB shares.

It currently has a buy rating and an $8.40 price target on them, which implies a potential upside of 13.5% for investors over the next 12 months.

The broker also expects a fully franked 3.9% dividend yield for FY 2024, boosting the total potential return to approximately 17.5%.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »